KR102320191B1 - 아람콜 염들 - Google Patents

아람콜 염들 Download PDF

Info

Publication number
KR102320191B1
KR102320191B1 KR1020167017460A KR20167017460A KR102320191B1 KR 102320191 B1 KR102320191 B1 KR 102320191B1 KR 1020167017460 A KR1020167017460 A KR 1020167017460A KR 20167017460 A KR20167017460 A KR 20167017460A KR 102320191 B1 KR102320191 B1 KR 102320191B1
Authority
KR
South Korea
Prior art keywords
salt
aramchol
arachidylamido
cholan
dihydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167017460A
Other languages
English (en)
Korean (ko)
Other versions
KR20160093051A (ko
Inventor
알렌 바하라프
이디트 에쉬카-오렌
Original Assignee
갈메드 리서치 앤드 디벨롭먼트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 갈메드 리서치 앤드 디벨롭먼트 리미티드 filed Critical 갈메드 리서치 앤드 디벨롭먼트 리미티드
Publication of KR20160093051A publication Critical patent/KR20160093051A/ko
Application granted granted Critical
Publication of KR102320191B1 publication Critical patent/KR102320191B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/05—Mono-, di- or tri-ethylamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020167017460A 2013-12-04 2014-12-04 아람콜 염들 Active KR102320191B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361911478P 2013-12-04 2013-12-04
US61/911,478 2013-12-04
PCT/IL2014/051052 WO2015083164A1 (en) 2013-12-04 2014-12-04 Aramchol salts

Publications (2)

Publication Number Publication Date
KR20160093051A KR20160093051A (ko) 2016-08-05
KR102320191B1 true KR102320191B1 (ko) 2021-11-03

Family

ID=53272986

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167017460A Active KR102320191B1 (ko) 2013-12-04 2014-12-04 아람콜 염들

Country Status (21)

Country Link
US (1) US20160304553A1 (enExample)
EP (1) EP3077047B1 (enExample)
JP (2) JP6675310B2 (enExample)
KR (1) KR102320191B1 (enExample)
CN (2) CN110437298A (enExample)
AU (2) AU2014358668B2 (enExample)
BR (1) BR112016012465B1 (enExample)
CA (1) CA2930232C (enExample)
CY (1) CY1121736T1 (enExample)
DK (1) DK3077047T3 (enExample)
ES (1) ES2732845T3 (enExample)
HR (1) HRP20191023T1 (enExample)
HU (1) HUE045209T2 (enExample)
LT (1) LT3077047T (enExample)
PL (1) PL3077047T3 (enExample)
PT (1) PT3077047T (enExample)
RS (1) RS59067B1 (enExample)
SI (1) SI3077047T1 (enExample)
SM (1) SMT201900363T1 (enExample)
TR (1) TR201909447T4 (enExample)
WO (1) WO2015083164A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL227890A0 (en) * 2013-08-08 2014-01-30 Galderm Therapeutics Ltd Antiaging compounds containing bile acid and fatty acid conjugates
TR201909447T4 (tr) * 2013-12-04 2019-07-22 Galmed Res & Development Ltd Aramkol tuzları.
US10849911B2 (en) 2015-06-10 2020-12-01 Galmed Research And Development Ltd. Low dose compositions of Aramachol salts
WO2017008902A1 (de) * 2015-07-12 2017-01-19 Cfso Gmbh Cholecalciferolsulfat-salze und deren verwendung zur behandlung von vitamin d3-mangel
WO2017017677A1 (en) * 2015-07-27 2017-02-02 Galmed Research And Development Ltd. Combination treatment for liver disease
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
FR3050112B1 (fr) 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
KR102399254B1 (ko) * 2016-09-28 2022-05-17 아이거 바이오파마슈티컬스 인코포레이티드 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물
US20190275061A1 (en) * 2016-11-10 2019-09-12 Galmed Research And Development Ltd Inhibition of fibrosis in non alcohol fatty liver disease patients
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
US11136347B2 (en) 2017-06-07 2021-10-05 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline forms of a fatty acid bile acid conjugate, preparation method thereof and use thereof
WO2019055280A1 (en) 2017-09-13 2019-03-21 Emmyon, Inc. DIETHANOLAMINE SALTS AND URSOLIC ACID MORPHOLIN
US20190183832A1 (en) * 2017-12-20 2019-06-20 Michael Guarnieri Nutritional bolus for animals
JP6612004B1 (ja) * 2018-07-31 2019-11-27 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
WO2020026471A1 (ja) * 2018-07-31 2020-02-06 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
JP2025529972A (ja) * 2022-09-02 2025-09-09 レックスファームテック カンパニー リミテッド 新規ベンフォチアミンコリン塩
US12090151B1 (en) 2023-05-12 2024-09-17 Michael Guarnieri Injectable sustained release buprenorphine formulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518881A (ja) * 2010-02-03 2013-05-23 武田薬品工業株式会社 アポトーシスシグナル調節キナーゼ１阻害剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2252863A (en) * 1941-02-03 1941-08-19 Searle & Co Quaternary ammonium salts
GB1532413A (en) * 1974-12-23 1978-11-15 Union International Co Ltd Chenodeoxycholic acid
IL123998A (en) * 1998-04-08 2004-09-27 Galmed Int Ltd Conjugates of bile salts and pharmaceutical preparations containing them
IL142650A (en) * 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
AU781524B2 (en) * 1999-10-13 2005-05-26 Johns Hopkins University School Of Medicine, The Regulators of the hedgehog pathway, compositions and uses related thereto
US8975246B2 (en) * 2001-04-17 2015-03-10 Galmed Research And Development Ltd. Bile acid or bile salt fatty acid conjugates
WO2005105091A1 (en) * 2004-04-28 2005-11-10 Merck & Co., Inc. Fluorinated 4-azasteroids as androgen receptor modulators
ITMI20061735A1 (it) * 2006-09-12 2008-03-13 Dipharma Spa Procedimento per la preparazione di acidi colanici
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
EP2391370B1 (en) * 2009-02-02 2015-06-03 Galmed Research and Development Ltd. Methods and compositions for treating alzheimer's disease
WO2011074607A1 (ja) * 2009-12-15 2011-06-23 明治製菓株式会社 トリテルペン誘導体およびｃ型慢性肝炎の予防または治療のための薬剤
CN102115486B (zh) * 2009-12-30 2015-06-03 上海特化医药科技有限公司 一种3-β-花生酰胺基-7α,12α,5β-胆烷-24-羧酸的制备方法
MX2012008801A (es) * 2010-01-28 2012-08-17 Merck Sharp & Dohme Composiciones farmaceuticas para el tratamiento de dolor y otras indicaciones.
ES2674174T3 (es) * 2010-12-07 2018-06-27 Bristol-Myers Squibb Company Antagonista de LPA1 policíclico y usos del mismo
TR201909447T4 (tr) * 2013-12-04 2019-07-22 Galmed Res & Development Ltd Aramkol tuzları.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518881A (ja) * 2010-02-03 2013-05-23 武田薬品工業株式会社 アポトーシスシグナル調節キナーゼ１阻害剤

Also Published As

Publication number Publication date
DK3077047T3 (da) 2019-07-15
EP3077047A1 (en) 2016-10-12
BR112016012465A8 (pt) 2020-05-05
RS59067B1 (sr) 2019-09-30
PL3077047T3 (pl) 2019-10-31
CA2930232C (en) 2020-09-15
CY1121736T1 (el) 2020-07-31
LT3077047T (lt) 2019-08-26
CN110437298A (zh) 2019-11-12
JP2020111584A (ja) 2020-07-27
KR20160093051A (ko) 2016-08-05
AU2019275638A1 (en) 2020-01-23
HK1226347A1 (zh) 2017-09-29
CN105848718A (zh) 2016-08-10
JP6675310B2 (ja) 2020-04-01
EP3077047A4 (en) 2017-05-03
WO2015083164A1 (en) 2015-06-11
AU2014358668A1 (en) 2016-06-02
SI3077047T1 (sl) 2019-09-30
CN105848718B (zh) 2019-07-30
HRP20191023T1 (hr) 2019-09-06
EP3077047B1 (en) 2019-04-24
HUE045209T2 (hu) 2019-12-30
JP2016539131A (ja) 2016-12-15
BR112016012465B1 (pt) 2023-04-18
SMT201900363T1 (it) 2019-09-09
CA2930232A1 (en) 2015-06-11
TR201909447T4 (tr) 2019-07-22
US20160304553A1 (en) 2016-10-20
AU2014358668B2 (en) 2019-10-24
ES2732845T3 (es) 2019-11-26
AU2019275638B2 (en) 2021-05-06
PT3077047T (pt) 2019-07-11

Similar Documents

Publication Publication Date Title
KR102320191B1 (ko) 아람콜 염들
CA2717326C (en) Preparation of lenalidomide
RU2754255C2 (ru) Новое кристаллическое твердое соединение гидрохлорида 3-фенил-4-пропил-1-(пиридин-2-ил)-1н-пиразол-5-ола
US20210046092A1 (en) Low dose compositions of aramchol salts
US11325943B2 (en) Crystalline salt forms of SBT-20
US20190276405A1 (en) Crystal of quinoline derivative
US20200277326A1 (en) Aramchol salts
US11571431B2 (en) Aramchol salts
US20210230213A1 (en) Aramchol salts
HK40014410A (en) Aramchol salts
HK1226347B (zh) Aramchol盐
WO2011027988A2 (en) Novel polymorphic form of prasugrel-hydrogen sulfate
EP3377478B1 (en) Co-crystals of bilastine
WO2017029408A1 (en) Solid state forms of sofosbuvir
HK1253978B (en) Co-crystals of bilastine
HK1253978A1 (en) Co-crystals of bilastine
WO2013024474A1 (en) Polymorphs of preladenant

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5